BioSpace News Archive

Pliant Therapeutics, Inc. announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis.

NanoString Technologies, Inc. announced that steps are being taken to protect its business, customers, employees and its mission to “Map the Universe of Biology.” With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware.

Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of “incisionless” endoluminal surgery.

Acepodia announced that the U.S. Food and Drug Administration has cleared the company’s investigational new drug application for ACE2016, an allogeneic gamma delta 2 T cell therapy for the treatment of epidermal growth factor receptor -expressing malignancies in patients with solid tumors.